Publications by authors named "In-Sil Choi"

Article Synopsis
  • Advanced biliary tract cancer (BTC) patients may benefit from fluoropyrimidine-based chemotherapy, but no direct comparisons between different regimens had been previously conducted.
  • An individual patient-level meta-analysis was performed using data from two clinical trials to evaluate overall survival (OS) across different chemotherapy regimens, including nal-IRI plus 5-FU/LV, mFOLFOX, and mFOLFIRI.
  • Results showed that nal-IRI plus 5-FU/LV significantly improved OS compared to both mFOLFOX and mFOLFIRI, with notable side effects differing among regimens; thus, considering both effectiveness and safety is essential in treatment decisions.
View Article and Find Full Text PDF

Purpose: This study evaluates the prognostic significance of tumor size at disease progression (PD) and depth of response (DOR) in cancer patients.

Materials And Methods: We performed post hoc analysis using data from six prospective clinical trials conducted by the Korean Cancer Study Group. Patients with tumor size at PD was categorized into 'Mild PD' and 'Significant PD' based on the cutoff values of relative change from baseline using maximally selected rank statistics.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates potential biomarkers to predict how breast cancer patients might respond to a combination of immunotherapy and chemotherapy, focusing on tumor samples from the KORNELIA trial.
  • Researchers analyzed genomic and transcriptomic data to differentiate between patients who had good progression-free survival (PFS) and those who did not, looking at factors like tumor mutation burden (TMB) and TP53 mutations.
  • Findings suggest that higher TMB and specific immune cell profiles correlate with better treatment outcomes, offering insights for future research on treatment combinations and biomarkers in HER-2-negative metastatic breast cancer.
View Article and Find Full Text PDF

Background/aim: This study investigated the treatment patterns and prognosis of patients with metastatic or unresectable colorectal cancer (mCRC) treated with chemotherapy with targeting agents.

Patients And Methods: This longitudinal multicenter study included 963 patients with mCRC who were treated in Korea between 2016 and 2020. Treatment patterns and efficacy were compared according to the mutation status and clinical factors.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to assess the safety and effectiveness of nivolumab combined with eribulin for treating metastatic breast cancer (specifically HR+HER2- and triple-negative BC) in Asian patients, enrolling 90 participants from 10 hospitals in Korea.
  • - Results showed that the six-month progression-free survival (PFS) rates were 47.2% for HR+HER2- patients and 25.1% for those with TNBC, with overall response rates at 53.3% and 28.9%, respectively.
  • - Common side effects included neutropenia and some immune-related adverse events, but the combination therapy indicated promising efficacy, suggesting potential benefits for further cancer treatments.
View Article and Find Full Text PDF

Purpose: In this study, we investigated the prognostic implications of focal breast edema on preoperative breast magnetic resonance imaging (MRI) in patients with breast cancer.

Methods: Data of 899 patients with breast cancer at a single institution were retrospectively analyzed. The patients were divided into an edema-positive group (EPG) and an edema-negative group (ENG) based on the presence of peritumoral, prepectoral, or subcutaneous edema.

View Article and Find Full Text PDF

Purpose: This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy.

Materials And Methods: Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator.

View Article and Find Full Text PDF

Background: Biliary tract cancers are rare, with a poor patient prognosis. Leptin and programmed death-ligand 1 (PD-L1) influence CD8 and forkhead box P3 (FOXP3) lymphocytes, and thus, cancer cell growth. We aimed to define the prognostic implications of these variables and the clinicopathological features of biliary tract cancers.

View Article and Find Full Text PDF

Skin rash is a well-known predictive marker of the response to cetuximab (Cmab) in metastatic colorectal cancer (mCRC). However, the mechanism of skin rash development is not well understood. Following exposure to EGFR-targeted therapies, changes in IL-8 levels have been reported.

View Article and Find Full Text PDF
Article Synopsis
  • The study compares the effects of 3 months versus 6 months of oxaliplatin combined with fluoropyrimidine as adjuvant therapy for high-risk stage II and III colorectal cancers (CRCs) to determine the optimal treatment duration while managing neurotoxicity.* -
  • A total of 1,788 patients participated, showing that while the longer 6-month treatment resulted in higher rates of neuropathy, the 3-month treatment had comparable 3-year disease-free survival (DFS) rates, particularly for stage III patients treated with capecitabine.* -
  • The findings suggest that the shorter 3-month treatment could be an effective alternative for patients with stage III CRC, providing a balance between efficacy and reduced side
View Article and Find Full Text PDF

Purpose: The 21-gene recurrence score (RS) assay is currently used for predicting chemotherapeutic benefits for hormone receptor-positive (HR +) early-stage breast cancer patients without consideration regarding racial differences in that predictive value. This study aimed at demonstrating racial differences in the predictive values of the 21-gene RS assay.

Methods: The study cohort was selected from the Surveillance, Epidemiology, and End Results (SEER) database.

View Article and Find Full Text PDF

Sweet syndrome is a neutrophilic dermatosis occasionally associated with malignancies. Due to its rarity, the clinical features of Sweet syndrome are still unclear. Thus, we aimed to analyze clinical features, treatment, and outcomes of these patients according to associated disease.

View Article and Find Full Text PDF

Rationale: An allergic transfusion reaction is a common side effect of transfusions of red blood cells. Using washed red blood cells is the most effective method for preventing such a reaction. However, the availability of other washed transfusion components, including platelets, is limited.

View Article and Find Full Text PDF

Background: In locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin. This study evaluated whether irinotecan/5-fluorouracil (5-FU; mFOLFIRI) was superior to oxaliplatin/5-FU (mFOLFOX) as a second-line treatment in BTC.

Patients And Methods: Patients diagnosed with BTC with disease progression after prior gemcitabine/cisplatin were randomised (1:1) to either mFOLFOX (control arm) or mFOLFIRI (experimental arm).

View Article and Find Full Text PDF

We investigated the prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer patients. BCL1 and BCL2 expression statuses were assessed by immunohistochemistry using tissue microarrays from 393 breast cancer patients. The Kaplan-Meier estimator and log-rank test were used for survival analyses.

View Article and Find Full Text PDF
Article Synopsis
  • Advanced breast cancer often spreads to bones, leading to mobility problems and reduced quality of life; standard treatments include bone-modifying agents and chemotherapy.
  • A study analyzed serum samples from breast cancer patients undergoing palliative treatment to identify biomarkers that might indicate better prognosis with zoledronic acid and taxane chemotherapy.
  • Key findings suggest that low levels of TGF-β1 and TNF-α, along with high levels of IFN-γ, are linked to longer progression-free survival (PFS), and a risk score based on these cytokines may help predict patient outcomes.
View Article and Find Full Text PDF

Radiation-induced cavernous malformations (RICMs) are most commonly reported in young patients who have previously received radiotherapy. Here, we report a case of a patient with a germ cell tumor who was treated with whole brain radiotherapy (WBRT) and then incidentally found to have numerous RICMs. A 31-year-old male visited the hospital for a testicular mass.

View Article and Find Full Text PDF

Multiple primary malignancies are defined as the presence of more than one malignant neoplasm with a distinct histology occurring at different sites in the same individual. They are classified as synchronous or metachronous according to the diagnostic time interval of different malignancies. Diagnosis of multiple primary malignancies should avoid misclassification from multifocal/multicentric tumors or recurrent/metastatic lesions.

View Article and Find Full Text PDF

Background: To evaluate the performance of the 21-gene recurrence score (RS) assay in predicting chemotherapy benefit in the Surveillance, Epidemiology, and End Results population, we aimed to assess breast cancer-specific mortality (BCSM) by chemotherapy use within each of the RS categories.

Methods: Data on breast cancer (BC) cases diagnosed between 2004 and 2015 with available RS results were released. Our analysis included patients with hormone receptor-positive, node-negative early-stage BC ( = 89,402), and three RS groups were defined; RS < 11, low; RS 11-25, intermediate; RS > 25, high.

View Article and Find Full Text PDF

Purpose: We aimed to investigate the clinicopathologic factors associated with distant metastasis (DM) and post-recurrence overall survival (OS) after salvage treatments for isolated locoregional recurrence (ILRR) of breast cancer and identify long-term surviving patients for providing a more personalized therapy.

Methods: We analyzed 125 patients who underwent salvage local treatments for ILRR after initial curative breast surgery.

Results: Fifty-two (41.

View Article and Find Full Text PDF

Background: The prognostic potential of PD-L1 is currently unclear in gastric carcinomas, although the immune checkpoint PD-1/PD-L1 inhibitors have produced promising results in clinical trials.

Methods: We explored the prognostic implications of programmed death ligand 1 (PD-L1) in 514 consecutive surgically-resected gastric carcinomas. Overall survival and recurrence-free survival were evaluated.

View Article and Find Full Text PDF

The Z0011 trial demonstrated that axillary lymph node dissection (ALND) could be omitted in spite of 1-2 metastatic sentinel lymph nodes. This study aimed to validate the results on a population-based database. The Surveillance, Epidemiology, and End Results (SEER) database was searched for patients comparable to the Z0011 participants.

View Article and Find Full Text PDF

We investigated the prognostic influence of androgen receptor (AR) on breast cancer. AR status was assessed using immunohistochemistry with tissue microarrays from 395 operable primary breast cancer patients who received curative surgery. The Kaplan-Meier estimator was used to analyze the survival rates and a log-rank test was used to determine the significance of the differences in survival.

View Article and Find Full Text PDF

Background: Although nonalcoholic fatty liver disease (NAFLD) has been linked to breast cancer risk, the actual relationship remains unclear. Fatty liver index (FLI) is a noninvasive method for predicting NAFLD. We aimed to assess the association between FLI, a predictor of NAFLD, and breast cancer risk.

View Article and Find Full Text PDF

Palbociclib, in conjunction with endocrine therapy, has been approved for the treatment of patients with advanced breast cancer. The common hematological toxicities associated with palbociclib are leukopenia and neutropenia. However, hematological malignancies have not been reported for palbociclib treatment.

View Article and Find Full Text PDF